临床肝胆病杂志2017，Vol.33Issue(1)：184-187,4.DOI:10.3969/j.issn.1001-5256.2017.01.043
经内镜逆行胰胆管造影术后胰腺炎的药物预防
Research advances in pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography
王艾(综述) 1赵礼金(审校)2
作者信息
- 1. 遵义医学院，贵州 遵义 563003
- 2. 遵义医学院附属医院 肝胆胰外科，贵州 遵义 563003
- 折叠
摘要
Abstract
Endoscopic retrograde cholangiopancreatography (ERCP)has become an important method for the diagnosis and treatment of cholangio -pancreatic duct diseases.Post -ERCP pancreatitis (PEP)is the most common complication and its incidence has increased up to 40% in recent years.The prevention of PEP has always been a hot topic in clinical research.This article reviews the research advances in the pharmacological prevention of PEP and points out that controlled clinical trials with a large sample size are still needed to investigate the effect of preventive drugs,and further studies should focus on optimal medication time,route of administration,and dose.In addition,de-mographic features of populations from different countries and different age groups should be taken into consideration.关键词
胰腺炎/胰胆管造影术,内窥镜逆行/化学预防/综述Key words
pancreatitis/cholangiopancreatography,endoscopic retrograde/chemoprevention/review分类
医药卫生引用本文复制引用
王艾(综述),赵礼金(审校)..经内镜逆行胰胆管造影术后胰腺炎的药物预防[J].临床肝胆病杂志,2017,33(1):184-187,4.
